Shakshuki Ayah, Yeung Pollen, Agu Remigius U
, BScPharm, MScPharm, is with the College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, BScPharm, PhD, is with the College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, BPharm, MPharm, PhD, is with the College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.
Can J Hosp Pharm. 2020 Mar-Apr;73(2):133-140. Epub 2020 Apr 1.
Topical amitriptyline has been described as having mixed clinical efficacy for neuropathic pain. A few case reports using higher concentrations of this compound found clinical benefit, but many of these studies did not describe the components used in formulating the amitriptyline preparations.
To generate reproducible clinical measures of the characteristics of amitriptyline diffusion from selected compounding bases, to support a scientific approach to base selection when compounding this drug for neuropathic pain.
Amitriptyline hydrochloride (1%, 5%, and 10%) was compounded with 3 proprietary compounding bases: Lipoderm base, Emollient Cream, and Mediflo 30 pluronic lecithin organogel (PLO) gel. In vitro release of the drug from each base and subsequent permeation across artificial human skin were investigated with the Franz diffusion system. Amitriptyline release mechanisms were determined with kinetic models. How quickly and to what extent the drug leaves each base to diffuse through the skin were characterized by determining steady-state flux, cumulative permeation, and lag times.
Release of amitriptyline was significantly higher from the Mediflo PLO gel than from the Lipoderm base or Emollient Cream ( < 0.05). Mean cumulative drug release after 24 h, from the 10% formulation, was 23.9% (standard deviation [SD] 4.1%) for Lipoderm base, 41.8% (SD 3.1%) for Emollient Cream, and 53.2% (SD 7.7%) for Mediflo PLO gel. A high percentage of amitriptyline was retained in all 3 bases. Although amitriptyline release was highest with Mediflo PLO gel, this base resulted in significantly lower cumulative permeation relative to Lipoderm base and Emollient Cream ( < 0.05). There was a strong overall correlation between amitriptyline concentration, lag time, and flux. Higher concentrations were associated with significantly lower lag times and increased flux. The highest lag time and flux were observed for Mediflo PLO gel.
These data indicate that the therapeutic effectiveness of compounded amitriptyline for neuropathic pain depends on its diffusion out of the compounding bases and penetration through the skin.
局部使用阿米替林治疗神经性疼痛的临床疗效存在差异。少数使用高浓度该化合物的病例报告显示有临床益处,但其中许多研究并未描述用于配制阿米替林制剂的成分。
生成从选定的复方基质中扩散出的阿米替林特性的可重复临床测量值,以支持在为神经性疼痛配制该药物时选择基质的科学方法。
将盐酸阿米替林(1%、5%和10%)与3种专利复方基质混合:Lipoderm基质、润肤霜和Mediflo 30普朗尼克卵磷脂有机凝胶(PLO)凝胶。使用Franz扩散系统研究药物从每种基质中的体外释放以及随后透过人造人皮的渗透情况。用动力学模型确定阿米替林的释放机制。通过测定稳态通量、累积渗透和滞后时间来表征药物离开每种基质并扩散穿过皮肤的速度和程度。
Mediflo PLO凝胶中阿米替林的释放量显著高于Lipoderm基质或润肤霜(<0.05)。对于10%的制剂,24小时后Lipoderm基质的平均累积药物释放量为23.9%(标准差[SD]4.1%),润肤霜为41.8%(SD 3.1%),Mediflo PLO凝胶为53.2%(SD 7.7%)。所有3种基质中都保留了高比例的阿米替林。尽管Mediflo PLO凝胶中阿米替林的释放量最高,但与Lipoderm基质和润肤霜相比,该基质导致的累积渗透量显著更低(<0.05)。阿米替林浓度、滞后时间和通量之间存在很强的总体相关性。较高浓度与显著更低的滞后时间和增加的通量相关。Mediflo PLO凝胶的滞后时间和通量最高。
这些数据表明,配制的阿米替林治疗神经性疼痛的疗效取决于其从复方基质中扩散出来并穿透皮肤的情况。